---
schema_version: "secwatch.filing_event.v1"
accession: "0001625297-26-000012"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2026-03-13T23:59:59+00:00"
generated_at: "2026-05-15T12:36:40.820850+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Indivior prices upsized $450M convertible notes at 0.625% due 2031

## Summary
- Principal amount $450M (upsized from $400M); 0.625% interest, matures March 15, 2031.
- Net proceeds ~$437.7M (~$486.4M if initial purchasers' option fully exercised).
- ~$239M of proceeds plus $102M cash used to repay term loan and revolver.
- Concurrent $75M repurchase of ~2.4M shares from note purchasers at market price.
- Initial conversion price ~$41.66/share, a 35% premium over March 12 closing price.

## SEC filing metadata
- accession: 0001625297-26-000012
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2026-03-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000012/0001625297-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000012/indv-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001625297-26-000012
- JSON: https://secwatch.observer/filing/0001625297-26-000012.json
- Plain text: https://secwatch.observer/filing/0001625297-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.